Skip to main content
      RT @RichardPAConway: Ghaffar et al. Chronic abdominal periaortitis. Imaging improved in only 57% and resolved in 9%. Inc

      Richard Conway RichardPAConway

      3 years 10 months ago
      Ghaffar et al. Chronic abdominal periaortitis. Imaging improved in only 57% and resolved in 9%. Incident aneurysms rare 8%. Older age and secondary cause assoc greater likelyhood improvement, smokers 2 times less likely. @RheumNow #ACR22 Abstr#1576 https://t.co/jS9djx3ZtU https://t.co/OFW2Jk7gGW
      RT @ericdeinmd: 13S150. Draft ACR/EULAR APLS Classif Crit #ACR22
      Entry: Clinical & +aPL w/in 3 yr
      Then: Additive cri

      Eric Dein ericdeinmd

      3 years 10 months ago
      13S150. Draft ACR/EULAR APLS Classif Crit #ACR22 Entry: Clinical & +aPL w/in 3 yr Then: Additive crit -Don't count other cause Clinical Domains: Macrovasc VTE, Macrovasc AT, Microvasc, Obst, Cardiac, Hematology Lab: +LA, aCL/B2GP IgM/IgG/titer Total: 3+ clin, 3+ lab @RheumNow https://t.co/YeKW0orjZC
      RT @DrTrishHarkins: ⬆️ serum anti-CCP3 Ab, absence IA
      👉 StopRA trial - ironically stopped🛑

      ❌ hydroxychloro

      Patricia Harkins DrTrishHarkins

      3 years 10 months ago
      ⬆️ serum anti-CCP3 Ab, absence IA 👉 StopRA trial - ironically stopped🛑 ❌ hydroxychloroquine not superior to PBO in preventing/ delaying IA 👉rate of conversion to RA in CCP3+ve ~35% @ 3yrs #ACR22 @RheumNow Abst#1604
      RT @KDAO2011: “As long as you are practicing rheumatology, your legal risk is low.” - @greerdonley, law professor, o

      TheDaoIndex KDAO2011

      3 years 10 months ago
      “As long as you are practicing rheumatology, your legal risk is low.” - @greerdonley, law professor, on how rheumatologists should not let fear of legal consequences interfere w/practicing high quality evidenced based medicine for our patients #ReproductiveRheum #ACR22 @rheumnow
      RT @RichardPAConway: Makol @AshimaMakol et al. Multimorbidity in SSc . SSc higher burden multimorbidity at diagnosis and

      Richard Conway RichardPAConway

      3 years 10 months ago
      Makol @AshimaMakol et al. Multimorbidity in SSc . SSc higher burden multimorbidity at diagnosis and higher risk of developing multimorbidity over time @RheumNow #ACR22 Abstr#1190 https://t.co/VopFI6U5G5 https://t.co/hKKPC7v8EN
      RT @uptoTate: CorEVITAS Abs 1499 #ACRbest #ACR22 cycling to a second line TNFi provides limited benefits to pts with AxS

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      CorEVITAS Abs 1499 #ACRbest #ACR22 cycling to a second line TNFi provides limited benefits to pts with AxSpA who discontinued a first line TNFi. @RheumNow https://t.co/fKDa5kPfXN https://t.co/CtMCj2Ihgc
      RT @RichardPAConway: Mazareeb et al. von Willebrand Factor in systemic vasculitis. Increased in active vasculitis compar

      Richard Conway RichardPAConway

      3 years 10 months ago
      Mazareeb et al. von Willebrand Factor in systemic vasculitis. Increased in active vasculitis compared to remission and HCs. Correlates disease activity. Not affected by IL6i. @RheumNow #ACR22 Abstr#1573 https://t.co/uJAFHQpOlu https://t.co/PNX0puOeCn
      RT @KDAO2011: Drop PJP prophylaxis in #SLE. Retrospec cohort 4900 SLE on MMF or CYP: 1 case of PJP detected over 2282 pe

      TheDaoIndex KDAO2011

      3 years 10 months ago
      Drop PJP prophylaxis in #SLE. Retrospec cohort 4900 SLE on MMF or CYP: 1 case of PJP detected over 2282 person years (incidence rate 0.44/1000 py); PJP prophylx cause neutropenia (IRR 4.7), leukopenia (IRR 4.0), C diff (IRR 3.9), hyperkalemia (IRR 3.7) abst#1594 ACR#22 @rheumnow
      RT @DrPetryna: #abs1601 #acr22 @rheumnow gender analysis of RCT 166 PsA pts on UST: F show ⬇️ response in resolution

      Olga Petryna DrPetryna

      3 years 10 months ago
      #abs1601 #acr22 @rheumnow gender analysis of RCT 166 PsA pts on UST: F show ⬇️ response in resolution of pain, enthesitis, dactylitis& ACR response rates in both mono and MTXcombo groups. Unlike M, F seem not to benefit from UST+MTX combo for improvement of enthesitis& dactylitis https://t.co/a0uao6eWDO
      RT @RichardPAConway: Papagoras et al. Serum GM-CSF increased in AxSpA and persists despite TNFi. Are we going to have a

      Richard Conway RichardPAConway

      3 years 10 months ago
      Papagoras et al. Serum GM-CSF increased in AxSpA and persists despite TNFi. Are we going to have a trial of mavrilimumab in AxSpA then? @RheumNow #ACR22 Abstr#1156 https://t.co/wCFsY9nC1p https://t.co/lrQQ7tIX4x
      RT @doctorRBC: BE COMPLETE study:
      Bimekizumab (IL-17A and IL-17F inhibitor) efficacious in phase 3 trial for treatment o

      Robert B Chao, MD doctorRBC

      3 years 10 months ago
      BE COMPLETE study: Bimekizumab (IL-17A and IL-17F inhibitor) efficacious in phase 3 trial for treatment of PsA. No new safety signals. Abs#1599 @RheumNow #ACR22 https://t.co/iXj7wSRNeK
      RT @uptoTate: Abs 1507 at #ACR22 demonstrated that even a 6-month delay in PsA dx from symptom onset contributes to wor

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      Abs 1507 at #ACR22 demonstrated that even a 6-month delay in PsA dx from symptom onset contributes to worse patient-reported outcomes measures on overall quality of life. @RheumNow https://t.co/qLOwE9rImz https://t.co/nacdjz5pCy
      RT @ericdeinmd: 13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22
      Lab Domains:
      LAC not always feasible to recheck
      aCL

      Eric Dein ericdeinmd

      3 years 10 months ago
      13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22 Lab Domains: LAC not always feasible to recheck aCL, aB2GP IgG higher risk, higher titers (>40U) @RheumNow https://t.co/rcQaqrtDN5
      RT @uptoTate: The likelihood of a patient self-reporting LDA/REM and specificity of MDA score were unaffected by which M

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      The likelihood of a patient self-reporting LDA/REM and specificity of MDA score were unaffected by which MDA criteria were met. @DrLauraCoates et al, Abs 1496 #ACR22 @RheumNow https://t.co/xH70swdZZ0 https://t.co/Wct0emTaDt
      RT @RichardPAConway: Juge @Juge_P_A @PhilippeDieude et al Excess of rare variants in JAK-STAT genes in RA-ILD vs RA 57%

      Richard Conway RichardPAConway

      3 years 10 months ago
      Juge @Juge_P_A @PhilippeDieude et al Excess of rare variants in JAK-STAT genes in RA-ILD vs RA 57% vs 46%;OR=1.37 95%CI[1.12-1.69]. Elucidates pathophysiology but also possible treatment rationale @RheumNow #ACR22 Abstr#1123 https://t.co/TAA0rODSmV https://t.co/2TjSY4CXDL
      ×